HALIFAX, Nov. 4, 2014 /CNW/ - MedMira, Inc. (MedMira)
(TSXV: MIR) announced today that Robyn
Cook has been appointed as the Company's Chief Corporate
Officer, effective immediately. Ms. Cook most recently served
as MedMira's Senior Director of Corporate Governance. She
will continue in her role as the Company's Corporate Secretary.
Ms. Cook brings a wealth of experience to the position of Chief
Corporate Officer, built on over 14 years working in a variety of
progressively senior roles at MedMira, spanning corporate
governance, compliance, operations, business process and policy
development, and human resources. As Chief Corporate Officer,
Ms. Cook will focus on organizational alignment and prioritization
of corporate strategy, implementation of industry best practices,
and maximizing excellence across all MedMira business units
"Robyn has been a valued member of the Company's senior
leadership team for many years, consistently delivering
results. The Board and management team look forward to
Robyn's continued contributions to MedMira's growth and success in
this new role," said Marvyn Robar,
Chairman of the Board, MedMira Inc. "With hands-on experience
and extensive knowledge of many of the key departments within our
organization, Robyn is uniquely qualified to strategically connect
and align the various parts of our business to drive performance
and results."
Prior to joining MedMira, Ms. Cook worked in the energy and
education sectors. She holds a Masters of Business
Administration from Saint Mary's
University, where the focus of her studies were corporate
governance best practices in public life sciences companies.
Ms. Cook also holds a Masters of Science, Nova
Scotia Agricultural College and a Bachelor of Science from
Dalhousie University.
Ms. Cook's appointment as MedMira's Chief Corporate Officer is
subject to final approval of the TSX Venture Exchange.
About MedMira
MedMira is a leading developer and manufacturer of vertical flow
rapid diagnostics. The Company's tests provide hospitals, labs,
clinics and individuals with instant diagnosis for diseases such as
HIV and hepatitis C in just three easy steps. The Company's tests
are sold under the Revealâ, Multiplo™ and Miriad™ brands
in global markets. Based on its patented Rapid Vertical Flow
Technology™, MedMira's rapid HIV test is the first one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible approval and launch of new products, future growth, and
new business opportunities. Actual events could materially
differ from those projected herein and depend on a number of
factors including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of
corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE MedMira Inc.